CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 400 enrolled
Drug / intervention
VRC-CHKVLP059-00-VP +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02562482
NCT02562482Phase 2Completed
CompareCT.gov

Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Sep 29, 2015·Updated Oct 22, 2020

In Brief

A Phase 2 clinical trial evaluating VRC-CHKVLP059-00-VP and VRC-PBSPLA043-00-VP for Chikungunya Virus Infection. Completed, enrolled 400 participants across 6 sites in 5 countries.

Detailed Summary

This is a multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2-injection vaccine Chikungunya virus (CHIKV) virus-like particle vaccine (CHIKV VLP) in healthy adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya Virus Infection
CountriesDominican Republic, Guadeloupe, Haiti, Martinique, Puerto Rico
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 29, 2015
Enrollment StartNov 18, 2015
Primary CompletionMar 6, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.8 years ago

Interventions

VRC-CHKVLP059-00-VPbiological

VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).

VRC-PBSPLA043-00-VPother

VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.